Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1%
Status:
Withdrawn
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the therapeutic equivalence of topical Adapalene Gel, 0.1 % and
Differin®(Adapalene) Gel, 0.1 % in the treatment of acne vulgaris and to demonstrate the
superiority of the efficacy of the test and reference products over the placebo.